# Implementation Roadmap

## 1. Executive Summary

The proposed system is an AI-assisted breast cancer diagnostic decision-support workflow. It is designed to analyse validated structured diagnostic information and provide a risk/decision-support output for review by qualified healthcare professionals.

The implementation follows a pilot-first strategy:

1. Governance and discovery
2. Data preparation
3. Model development and local validation
4. Secure product development and integration
5. Silent-mode testing
6. Controlled clinical pilot
7. Formal evaluation
8. Scale-up and continuous monitoring

The final clinical decision remains with the qualified healthcare professional.

## 2. Technical Workflow

```text
Authorised Clinical Data
        ↓
Input Validation & Eligibility Check
        ↓
Preprocessing
        ↓
Validated AI/ML Model
        ↓
Risk / Decision-Support Output
        ↓
Explanation + Confidence Information
        ↓
Clinician Review & Override
        ↓
Clinical Workflow
        ↓
Audit Logs + Monitoring
```

## 3. 12-Month Plan

| Phase | Timeline | Main Output |
|---|---|---|
| Governance & discovery | Months 1–2 | Use case, scope, risk plan |
| Data preparation | Months 2–4 | Validated dataset |
| Model validation | Months 3–5 | Local validation report |
| Product & integration | Months 4–7 | Secure pilot system |
| Silent-mode pilot | Months 7–8 | Reliability/workflow evidence |
| Controlled clinical pilot | Months 9–10 | Pilot evaluation |
| Scale decision | Month 11 | Go/No-Go recommendation |
| Scale & monitoring | Month 12+ | Controlled expansion |

## 4. Core Safety Principles

- Human-in-the-loop clinical decision making
- No autonomous treatment decisions
- Manual fallback when AI is unavailable
- Out-of-scope cases should not be forced through the model
- Model version and prediction events should be auditable
- Performance should be monitored after deployment
- Significant model changes require revalidation

## 5. Evaluation

Suggested evaluation dimensions:

- Sensitivity
- Specificity
- Precision
- Recall
- F1-score
- AUROC
- Calibration
- False-negative behaviour
- Subgroup performance
- Response time
- Uptime
- User adoption
- Override frequency
- Alert burden
- Safety incidents

## 6. Scalability

The system should be expanded only after the pilot demonstrates acceptable safety, performance, usability, reliability and operational value. Each new site should undergo local data-quality assessment and validation because patient populations and workflows may differ.

## 7. Disclaimer

Educational project only. Not a clinical diagnostic system.
